Company news
Cstone Pharmaceuticals (HKEX:2616) news
Cstone Pharmaceuticals news releases on 6ix. Latest, Sep 28, 2026: INTERIM REPORT 2026
Press releases & updates
INTERIM REPORT 2026
September 28, 2026
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
August 27, 2026
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
June 25, 2026
CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
June 11, 2026
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
May 31, 2026
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
April 18, 2026
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
March 26, 2026
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
February 21, 2026
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 to Advance into Phase II Clinical Trial
February 16, 2026
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
February 14, 2026
ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut
November 5, 2025
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
October 18, 2025
CStone Announces 2025 Interim Results, Pipeline Acceleration and Value Potential Unlocked
August 15, 2025
CStone Signs Exclusive License Agreement with Istituto Gentili for Sugemalimab in Western Europe and the UK
July 8, 2025
CStone Announces Clinical Progress Update on CS2009
July 7, 2025
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
May 5, 2025
CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR
May 4, 2025
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
March 27, 2025
CStone to Showcase Five Latest Research Achievements at AACR 2025
March 24, 2025
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
March 22, 2025
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
March 4, 2025
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
March 2, 2025
CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab in JAMA
February 26, 2025
CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA
February 23, 2025
CStone Announces Inclusion of Cejemly as a First-Line Combination Therapy for NSCLC in ESMO Guideline
February 10, 2025
CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody
December 23, 2024
CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer in the UK
November 1, 2024